Marinov et al. 200425
|
RET / 68a
|
Oral NMP 200 mg bd for ≥ 14 days
|
Oral NMP administered for average of 21 days.
Overall, 88% of patients were discharged from hospital with a healthy
pregnancy.
|
Turgal et al. 201726
|
OL, RCT / 60b
|
Oral NMP 400 mg/day for 4 weeks vs
No treatment
|
Mean placental volume increased more in oral NMP group vs control
group: 336% (67–1077) vs 141% (29–900), p =
0.007.
No between-group differences in mean change for gestational sac,
amniotic sac, or embryonic volumes.
No difference between oral NMP vs control for secondary endpoints
including live birth rate (92.9% vs 96.4%, p =
0.55) and mean gestational age at delivery (38.0 ± 2.8 vs
38.5 ± 1.6 weeks, p = 0.46).
|
Siew et al. 201827
|
OL, RCT / 118c
|
Oral NMP 200 mg bd vs
Oral DYD 10 mg bd, both for 2 weeks
|
No difference between oral NMP and oral DYD groups for miscarriage rate
at ≤16 weeks (10.2% vs 15.2%, p = 0.581).
No difference in extent of bleeding at days 4–10: 89.7% of oral NMP
recipient vs 96.6% of DYD recipients reported
similar/less/resolved bleeding vs baseline, p =
0.272.
|